The molecular levels of TARBP2 were explored to demonstrate its impact on the clinical outcomes in HCC patients, showing association with tumor stages and the OS of HCC patients within three-year after initial diagnosis, after controlling gender and age. The gene discussed is TARBP2; the disease is hepatocellular carcinoma.